Tag Archives: Ronald Scott

Adesh Kaul will join Basilea Pharmaceutica’s Management Committee as Chief Corporate Development Officer

Posted on 5, March 2018 by

BASEL, 05-Mar-2018 — /EuropaWire/ — Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that Adesh Kaul will join Basilea’s Management Committee as Chief Corporate Development Officer effective March 01, 2018. He will continue to be responsible for strategic planning, business development & … Read the full press release →

Posted in Pharma & Biotech, Switzerland

Tagged , , , , ,

U.S. FDA designated Basilea Pharmaceutica’s isavuconazole as Qualified Infectious Disease Product (QIDP) for the treatment of invasive aspergillosis

Posted on 11, December 2013 by

Basel, Switzerland, 11-12-2013 — /EuropaWire/ — Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that the U.S. Food and Drug Administration (FDA) designated isavuconazole as a Qualified Infectious Disease Product (QIDP) for the treatment of invasive aspergillosis. QIDP status provides priority review and … Read the full press release →

Posted in Government, Healthcare, Pharma & Biotech, Switzerland

Tagged , , , , , , , , , , , ,

Basilea Pharmaceutica Ltd awarded USD 89M contract by U.S. Department of Health and Human Services division BARDA for the development of its novel antibiotic BAL30072

Posted on 26, June 2013 by

BAL30072 current multiple ascending dose study reached maximum tolerated dose Further development, including combination studies with carbapenems, planned under BARDA agreement Basel, Switzerland, 26-6-2013 — /europawire.eu/ — Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that the Biomedical Advanced Research and Development … Read the full press release →

Posted in Business, Financial, Healthcare, Pharma & Biotech, Switzerland

Tagged , , , , ,